原发性皮肤CD30+间变性大细胞淋巴瘤临床及组织病理分析

目的：探讨原发性皮肤CD30 间变性大细胞淋巴瘤(ALCL)的临床及组织病理学特征。方法：对3例患者的皮损行组织病理学及免疫组化检查,观察原发性皮肤CD30 ALCL组织病理学特征及CD45、CD3、CD20、CD30、EMA、HMB45等抗体染色结果。结果：3例患者临床上均表现为皮下结节。组织病理学特征为肿瘤细胞异形性明显,呈多形性,胞质丰富,核大,核仁明显。CD30标记阳性,不表达T细胞标记CD45RO及CD3。结论：原发性皮肤CD30 ALCL是具有独特形态特点及临床特征的肿瘤,根据组织学特征及免疫组化CD30阳性,可与其他恶性肿瘤进行鉴别。     

皮肤原发性间变性大细胞淋巴瘤—附1例报告

报道1例皮肤原发性间变性大细胞淋巴瘤。运用HE染色观察组织学形态及LCA、UCHL1、L26、CD30、EMA等抗体的免疫组化染色,以确定本例肿瘤的免疫表型。结果本例瘤细胞表达CD30、EMA及T细胞相关抗原。皮肤原发性间变性大细胞淋巴瘤临床经过缓慢,预后良好。     

原发性皮肤CD30阳性淋巴组织增生性疾病临床病理分析

目的 探讨原发性皮肤CD30阳性淋巴组织增生性疾病的临床及病理学特征。方法 对4例淋巴瘤样丘疹病及5例原发性皮肤间变性大细胞淋巴瘤的临床、病理学特征及免疫组化表达进行分析。结果 淋巴瘤样丘疹病分为A、B、C三型,组织学上形成一个连续的谱系,A型见多形性间变性大细胞或Sternberg-Reed样细胞散在分布或小片状分布在多量炎性细胞背景中;B型类似蕈样肉芽肿病变,表现为真皮层较宽的淋巴细胞浸润带,其中散在少量小至中等异形脑回样淋巴细胞;C型以间变性大细胞弥漫分布为特征,但临床上可自行消退。原发性皮肤间变性大细胞以皮下结节或皮肤丘疹就诊,瘤细胞体积大,呈多形性、圆形或椭圆形,胞质丰富,嗜酸或呈双色性,核大,核仁明显。两组病变中的大细胞均特征性表达CD30,预后均较好。结论 原发性皮肤CD30阳性淋巴组织增生性疾病是一组预后较好的皮肤T细胞性淋巴瘤谱系,综合临床表现、组织病理改变、免疫组化有助于本病的诊断。     

原发性皮肤CD30~+间变大细胞淋巴瘤一例

<正>原发性CD30+间变大细胞淋巴瘤(CD30positive anaplastic large cell lymphoma,ALCL)是一种少见的非霍奇金淋巴瘤,主要发生于淋巴结和结外的皮肤及皮下组织。我科收治1例临床罕见的以皮肤结节及溃疡为表现的面部原发性CD30+间变大细胞淋巴瘤,现报告如下。临床资料患者,女,74岁。主因右侧面部反复出现结节、溃疡,伴轻度疼痛4个月,于2011年5月就诊。患     

原发皮肤CD30阳性间变大细胞淋巴瘤七例临床病理分析

目的 探讨原发皮肤CD30阳性间变大细胞淋巴瘤（PC-ALCL）的临床与组织病理学特征。 方法 回顾性分析7例PC-ALCL患者的临床及病理资料情况。 结果 7例患者中,男6例,女1例,平均发病年龄52岁。皮损为红色结节、肿块和（或）斑块,3例多发,4例单发,6例伴溃疡形成。所有患者均未见系统受累。组织病理改变：肿瘤细胞在真皮内弥漫性分布,细胞体积大,胞质丰富,胞核呈异形改变,可见核分裂象。肿瘤细胞CD30和细胞毒蛋白阳性,CD20、CD56、间变性淋巴瘤激酶（ALK）和EB病毒编码小RNA原位杂交均阴性。结论 PC-ALCL是一种少见的原发于皮肤的低度恶性T细胞淋巴瘤,结合临床表现、皮损组织病理及免疫组化检查可确诊,罕见系统受累及转移。     

原发性皮肤CD30+间变性大细胞淋巴瘤1例

报告1例原发性皮肤CD30+间变性大细胞淋巴瘤.患者男,72岁.右足拇趾红肿,外侧有一2.0 cm×2.5 cm红色溃疡面,伴血性液体渗出,近端有一1.5 cm×2.0 cm暗红色结节,表面结痂.皮损组织病理及免疫组化标记确诊为原发性皮肤CD30+间变性大细胞淋巴瘤.     

泛发性原发皮肤CD30+间变性大细胞淋巴瘤

报告1例泛发性原发皮肤CD30+问变性大细胞淋巴瘤.患者男,44岁.因全身皮肤多发红斑、结节、溃疡50余天就诊,皮损组织病理及免疫组化检查结果提示间变性大细胞淋巴瘤,免疫组化检查:瘤细胞CD3(++),CD30(++),Ki-67约50%(+),CD20、Ckpan、S-100蛋白、HMB45、间变性淋巴瘤激酶(ALK)-1均阴性,诊断为间变性大细胞淋巴瘤.     

原发性皮肤间变性大细胞淋巴瘤

报告1例原发性皮肤间变性大细胞淋巴瘤.患者男,80岁.因右小腿丘疹、结节伴瘙痒2个月就诊.体格检查发现右小腿胫前数十个孤立的丘疹、结节.皮损组织病理检查示真皮全层大细胞弥漫浸润,细胞核呈间变性;免疫组化染色示CD30(+),间变性淋巴瘤激酶(ALK-1)(-).结合临床,诊断为原发性皮肤间变性大细胞淋巴瘤.     

原发性皮肤间变性大细胞淋巴瘤1例并临床分析

原发性皮肤间变性大细胞淋巴瘤是临床少见的一种皮肤肿瘤。其临床特征为原发于老年人皮肤的红色结节或肿瘤,病理特征为CD30阳性大细胞的大量表达(>75%)。治疗采用减量CHOP方案,效果明显。     

原发性皮肤间变性大细胞淋巴瘤1例

报告1例原发性皮肤间变性大细胞淋巴瘤。患者女,49岁。右小腿结节1年,溃烂5个月。皮损组织病理检查:真皮内有密集的淋巴样细胞浸润,瘤细胞大、核呈肾形或不规则形、核分裂像多见,免疫组化示瘤细胞约70?30阳性、约20?45Ro阳性,而CD3、CD20、MPO、TIA-1、ALK-1均为阴性。诊断为原发性皮肤间变性大细胞淋巴瘤。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.